What Causes Low Estrogen in Women?

The Ovarian Estrogen System: Why It Fails

The ovaries produce roughly 80 to 90% of circulating estradiol in premenopausal women. Estradiol synthesis requires functioning follicles, intact hypothalamic-pituitary signaling, and adequate substrate (cholesterol and adrenal precursors). When any link in that chain breaks down, serum estradiol falls [1].

The hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulses, which drives the pituitary to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). FSH stimulates ovarian follicles; the follicles produce estradiol. When follicle reserves drop or hypothalamic pulsatility is disrupted, estradiol output falls and FSH rises as the pituitary attempts to compensate [2].

Why the Distinction Between "Central" and "Ovarian" Causes Matters

Causes that originate in the hypothalamus or pituitary are called central (low FSH, low LH). Causes that originate in the ovary itself produce high FSH and high LH because the pituitary is working harder to stimulate a failing ovary. This FSH pattern is the single most useful initial lab finding for narrowing the cause [3].

Normal Estradiol Reference Ranges

Estradiol varies enormously across the menstrual cycle. The follicular-phase range is roughly 30 to 120 pg/mL, the mid-cycle peak reaches 200 to 400 pg/mL, and the luteal phase settles around 60 to 150 pg/mL. Postmenopausally, estradiol typically falls below 20 pg/mL, and in surgical menopause it may fall below 10 pg/mL within days of oophorectomy [4].

Menopause: The Most Common Cause

Natural menopause is defined as 12 consecutive months without a menstrual period and occurs at a median age of 51.4 years in the United States [5]. The mechanism is follicular depletion. A woman is born with roughly 1 to 2 million primordial follicles; by the early 40s the remaining pool is too small to sustain adequate estradiol production [6].

The Perimenopause Transition

Estradiol does not decline in a straight line. During perimenopause, which may begin 4 to 10 years before the final menstrual period, estradiol fluctuates dramatically. Some cycles produce estradiol surges above 300 pg/mL; others produce near-postmenopausal levels below 20 pg/mL. The SWAN (Study of Women's Health Across the Nation, N=3,302) documented that FSH begins rising measurably an average of 6 years before the final menstrual period [7].

Symptom Burden at Menopause

Vasomotor symptoms (hot flashes, night sweats) occur in up to 80% of women during the menopause transition. Genitourinary syndrome of menopause (GSM), including vaginal dryness and dyspareunia, affects at least 45% of postmenopausal women, yet fewer than 25% seek treatment [8]. Both are direct consequences of falling estradiol.

Premature Ovarian Insufficiency

POI is diagnosed when ovarian function becomes irregular or ceases before age 40. The 2016 European Society of Human Reproduction and Embryology (ESHRE) guideline defines POI as oligomenorrhea or amenorrhea for at least 4 months combined with FSH >25 IU/L on two measurements at least 4 weeks apart [9].

Causes Within POI

POI is not a single disease. Known causes include:

• Chromosomal abnormalities. Turner syndrome (45,X) accounts for up to 10 to 15% of POI cases. Fragile X premutation (FMR1 CGG repeat expansion of 55 to 200 repeats) carries a 20% lifetime risk of POI [10].
• Autoimmune oophoritis. Autoimmune adrenal insufficiency (Addison disease) co-occurs with POI in roughly 20% of autoimmune POI cases. Anti-21-hydroxylase antibodies are the recommended initial screen [9].
• Idiopathic POI. In approximately 75 to 90% of cases, no cause is identified despite full workup [11].

Fertility and Bone Implications

Women with POI have spontaneous pregnancy rates of about 5 to 10% because intermittent follicular activity can persist. Bone mineral density declines faster in untreated POI than in age-matched controls because of the longer duration of estrogen deficiency. ESHRE guidelines recommend hormone therapy until at least the natural age of menopause (approximately age 51) to protect bone and cardiovascular health [9].

Hypothalamic Amenorrhea: Low Estrogen From the Brain Down

Hypothalamic amenorrhea (HA) occurs when the hypothalamus suppresses GnRH pulsatility, causing downstream loss of FSH, LH, and estradiol. Unlike menopause or POI, FSH and LH are low or low-normal, and the ovaries contain healthy antral follicles. The three recognized triggers are energy deficiency, psychological stress, and excessive exercise, and all three often coexist [12].

Energy Availability and the REDs Framework

The International Olympic Committee's Relative Energy Deficiency in Sport (RED-S) consensus defines the danger threshold as energy availability below 30 kcal per kilogram of fat-free mass per day. Below that threshold, the hypothalamus reduces GnRH pulse frequency within days. A 2014 controlled feeding study (N=29) published in the Journal of Clinical Endocrinology and Metabolism confirmed that reducing energy availability to 10 kcal/kg fat-free mass per day suppressed LH pulsatility by 50% within 5 days [13].

Body Weight and BMI Thresholds

Estrogen production requires a minimum body-fat percentage. Studies consistently identify hypothalamic dysfunction appearing when body fat falls below approximately 17 to 22% or BMI drops below 17.5 to 18.5 kg/m². Women with anorexia nervosa have measured estradiol levels as low as 5 pg/mL, comparable to surgically menopausal women [14].

Treatment of Hypothalamic Amenorrhea

The Endocrine Society's 2017 Clinical Practice Guideline on functional hypothalamic amenorrhea recommends energy restoration as the primary treatment, not exogenous estrogen, because covering a nutritional deficit with hormones does not restore bone fully and masks the underlying problem [12]. However, estrogen therapy is appropriate if bone loss is already documented and the underlying cause cannot be rapidly corrected.

Surgical Menopause: Oophorectomy

Removal of both ovaries (bilateral oophorectomy) causes an immediate and complete loss of ovarian estradiol. Estradiol may fall from a premenopausal level of 100 to 200 pg/mL to below 10 pg/mL within 24 to 48 hours of surgery [15]. The abruptness makes surgical menopause symptomatically more severe than natural menopause for most women.

A 2019 cohort analysis in the Journal of Clinical Oncology (N=1,218 women with BRCA mutations) found that bilateral risk-reducing salpingo-oophorectomy before age 45 without hormone therapy was associated with a 1.78-fold increase in all-cause mortality compared with women who received HRT after the procedure [16]. This finding reinforces guideline recommendations to offer estrogen therapy to all women under 51 who undergo bilateral oophorectomy unless a strong contraindication exists.

Elevated Prolactin: Hyperprolactinemia

Prolactin, secreted by the pituitary, inhibits GnRH pulsatility when elevated. Hyperprolactinemia is defined as serum prolactin above 25 ng/mL in most labs. Causes include prolactinoma (the most common pituitary tumor), dopamine-blocking medications, hypothyroidism, and chronic renal failure [17].

Prolactinomas are treated with dopamine agonists, most commonly cabergoline 0.5 to 2 mg twice weekly. Normalization of prolactin typically restores GnRH pulsatility and estradiol within 4 to 8 weeks. In a randomized trial (N=459) from the New England Journal of Medicine, cabergoline normalized prolactin in 83% of patients versus 59% with bromocriptine (P<0.001) [18].

Medications That Suppress Estrogen

GnRH Agonists and Antagonists

GnRH agonists including leuprolide (Lupron), nafarelin, and buserelin are used to treat endometriosis, uterine fibroids, and as part of prostate cancer or gender-affirming care protocols. Continuous (non-pulsatile) GnRH agonist exposure downregulates pituitary GnRH receptors, suppressing FSH and LH and dropping estradiol to postmenopausal levels within 2 to 4 weeks [19].

GnRH antagonists (cetrorelix, ganirelix, elagolix, relugolix) act more rapidly, producing castrate-level estradiol within days rather than weeks. Elagolix, approved by the FDA in 2018 for endometriosis, produces dose-dependent estradiol suppression: 150 mg once daily yields partial suppression (estradiol roughly 41 pg/mL), while 200 mg twice daily yields near-complete suppression (estradiol roughly 12 pg/mL) [20].

Aromatase Inhibitors

Aromatase inhibitors (AIs), including anastrozole, letrozole, and exemestane, block peripheral conversion of androgens to estrogens. They are used in breast cancer treatment and sometimes in ovulation induction. In postmenopausal breast cancer patients, AIs reduce serum estradiol by more than 95%, to levels below 1 pg/mL [21].

Premenopausal women who take AIs without simultaneous ovarian suppression may experience a reflexive FSH rise that stimulates ovarian follicles and partially overcomes the AI. This is why AI-based breast cancer therapy in premenopausal women requires concurrent ovarian suppression with a GnRH agonist [22].

Antipsychotics and Other Dopamine Blockers

Dopamine normally suppresses prolactin release. Medications that block dopamine receptors, including haloperidol, risperidone, metoclopramide, and older antipsychotics, raise prolactin secondarily. Risperidone, in particular, raises prolactin more than other atypical antipsychotics because it crosses the blood-brain barrier less efficiently and has higher D2 affinity in the pituitary [23].

Radiation and Chemotherapy

Pelvic radiation above approximately 6 Gy delivered to the ovaries causes permanent follicle destruction. Total body irradiation, used in bone marrow transplantation, consistently causes POI in adult women [24]. Ovarian transposition (oophoropexy), performed before pelvic radiation, moves the ovaries outside the radiation field and preserves function in up to 60 to 90% of cases.

Alkylating chemotherapy agents (cyclophosphamide, busulfan, melphalan) are the most gonadotoxic cytotoxic drugs. The American Society for Reproductive Medicine (ASRM) classifies cyclophosphamide as high-risk for gonadotoxicity at cumulative doses above 7.5 g/m² [25]. Gonadotropin-releasing hormone agonist co-treatment during chemotherapy to temporarily suppress ovarian activity has been studied as a protective strategy, with a 2015 NEJM trial (POEMS, N=257) showing that goserelin co-treatment preserved ovarian function in 89% of premenopausal women with breast cancer vs. 67% in the control arm (P=0.02) [26].

Chronic Illness, Thyroid Dysfunction, and Other Medical Causes

Thyroid Disease

Both hypothyroidism and hyperthyroidism disrupt the menstrual cycle and estrogen metabolism. Hypothyroidism raises TBG (thyroid-binding globulin), which alters sex-hormone-binding globulin (SHBG) levels and total estrogen metabolism. Severe hypothyroidism may also raise prolactin through increased thyrotropin-releasing hormone (TRH) stimulation of prolactin cells. Treating the thyroid disorder typically restores the hormonal axis without additional estrogen therapy [27].

Turner Syndrome and Other Chromosomal Conditions

Turner syndrome affects 1 in 2,000 female births and is the most common chromosomal cause of POI. Most women with Turner syndrome have streak gonads that never produce adequate estradiol. Estrogen replacement initiated at the expected pubertal age (11 to 12 years) is recommended by the Endocrine Society to induce puberty and protect long-term bone health [28].

Chronic Kidney Disease

Advanced chronic kidney disease (CKD, stages 4 to 5) disrupts the hypothalamic-pituitary-ovarian axis through uremic toxin accumulation, hyperprolactinemia, and altered gonadotropin clearance. Women with end-stage renal disease have estradiol levels 50 to 70% below age-matched healthy controls in some cross-sectional data [29].

Lifestyle Factors That Reduce Estrogen

Body Composition

Adipose tissue is a significant source of peripheral estrogen production via aromatase after menopause. Paradoxically, very low body fat suppresses estrogen in premenopausal women (through the hypothalamic pathway), while excessive fat in postmenopausal women may modestly raise estrogen and increase breast cancer risk. The optimal body-fat range for hormonal health in premenopausal women is generally cited at 20 to 30% [30].

Alcohol, Smoking, and Diet

Chronic heavy alcohol use raises SHBG, which reduces free estradiol, and disrupts the hypothalamic-pituitary axis. Smoking accelerates the enzymatic degradation of estradiol to less potent metabolites and is associated with a 1 to 2 year earlier menopause onset in population data [31].

Diets extremely low in fat reduce the cholesterol substrate available for steroid hormone synthesis. A study in the American Journal of Clinical Nutrition (N=64) found that women on diets providing <15% of calories from fat had serum estradiol levels roughly 18% lower than those on standard diets after 2 months [32].

Diagnosing Low Estrogen: The Clinical Workup

A standard workup for suspected estrogen deficiency includes:

• Serum estradiol (follicular phase or random if amenorrheic)
• FSH and LH (distinguishes central from ovarian cause)
• Prolactin (screens for hyperprolactinemia)
• TSH (screens for thyroid disease)
• AMH (anti-Müllerian hormone) (reflects ovarian reserve; low in POI and approaching menopause)
• Karyotype (if POI is confirmed before age 35)
• FMR1 premutation testing (if POI is confirmed)
• Anti-21-hydroxylase antibodies (screens for autoimmune oophoritis)
• Pelvic ultrasound (antral follicle count supports ovarian reserve assessment)
• DEXA scan (bone mineral density, particularly if amenorrhea has persisted >6 months) [3, 9]

The Endocrine Society's 2015 guideline on POI states: "We recommend that all women with newly diagnosed POI be informed of their diagnosis as early as possible by a physician with the skills to clearly communicate the diagnosis and its implications." This underscores that a careful, comprehensive conversation with the patient, not just a lab panel, is the standard of care [3].

Treatment Options Matched to Cause

| Cause | First-Line Treatment | Notes | |---|---|---| | Natural menopause | Estrogen-progestogen HRT or estrogen-only (if no uterus) | FDA-approved; see NAMS 2022 position statement | | POI | HRT to age ~51 | Higher doses often needed vs. Standard menopause HRT | | Hypothalamic amenorrhea | Energy restoration, stress reduction | Estrogen if bone loss documented | | Surgical menopause <51 | Systemic estrogen (oral or transdermal) | Start within weeks of surgery | | Hyperprolactinemia | Cabergoline 0.5 to 2 mg twice weekly | Restores estradiol in most women within 2 months | | GnRH agonist-induced | Estrogen add-back therapy | Guideline-supported after 6 months of GnRH agonist use | | Aromatase inhibitor | Manage cancer first; add ovarian suppression if premenopausal | AI plus GnRH agonist is standard in premenopausal HR+ breast cancer | | Chemotherapy/radiation | Fertility preservation before treatment; HRT after if oncologically appropriate | ASRM guidelines apply |